Accelerating the Development of Enabled Formulations for Poorly Soluble Drugs using Translational Pharmaceutics

This white paper describes the benefits of our approach to poorly soluble drugs in terms of drug product performance and clinical decision-making, including case studies that demonstrate significant time and cost savings.